Literature DB >> 7718203

Atypical pneumonias in children.

M R Hammerschlag1.   

Abstract

The major agents responsible for atypical pneumonia in children include a wide variety of organisms, one Mycoplasma species, two Chlamydia species, a rickettsia, and one fastidious bacterium. Mycoplasma pneumoniae and C. pneumoniae together may be responsible for over 40% of these infections. Recognition of the role that these agents play in pneumonia is important since many of the diagnostic methods used to detect these organisms are not available in most hospital microbiology laboratories. If you don't look, you won't find. Epidemiologic factors can provide valuable clues, especially with the less frequently encountered infections, since it is almost impossible to make a clinical diagnosis on which to base treatment. A reliable history of avian exposure should suggest psittacosis, exposure to sheep or pregnant cats suggests Q fever, and children with underlying malignancy or immunodeficiency or those receiving systemic steroids may have legionnaires' disease. None of these organisms are susceptible to beta-lactam antibiotics. Sometimes the diagnosis is not considered until after the child has failed to respond to a penicillin or a cephalosporin and routine bacteriology is negative. In view of the role played by M. pneumoniae and C. pneumoniae, a macrolide may be the first-line antibiotic for atypical pneumonia in children.

Entities:  

Mesh:

Year:  1995        PMID: 7718203

Source DB:  PubMed          Journal:  Adv Pediatr Infect Dis        ISSN: 0884-9404


  5 in total

Review 1.  Clinical use of cefuroxime in paediatric community-acquired pneumonia.

Authors:  C Olivier
Journal:  Paediatr Drugs       Date:  2000 Sep-Oct       Impact factor: 3.022

Review 2.  Asthma in children: are chlamydia or mycoplasma involved?

Authors:  S Esposito; N Principi
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Commonly used antibacterial and antifungal agents for hospitalised paediatric patients: implications for therapy with an emphasis on clinical pharmacokinetics.

Authors:  J Singh; B Burr; D Stringham; A Arrieta
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

4.  Diagnosis of Mycoplasma pneumoniae pneumonia in children.

Authors:  M E Waris; P Toikka; T Saarinen; S Nikkari; O Meurman; R Vainionpää; J Mertsola; O Ruuskanen
Journal:  J Clin Microbiol       Date:  1998-11       Impact factor: 5.948

5.  Clinical Evaluation of a Novel Point-of-Care Assay To Detect Mycoplasma pneumoniae and Associated Macrolide-Resistant Mutations.

Authors:  Toshihiko Kakiuchi; Ippei Miyata; Reiji Kimura; Goh Shimomura; Kunihisa Shimomura; Satoru Yamaguchi; Takato Yokoyama; Kazunobu Ouchi; Muneaki Matsuo
Journal:  J Clin Microbiol       Date:  2021-06-18       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.